Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Nucleic acid drug delivery system, preparation method, pharmaceutical composition and application

A nucleic acid drug and delivery system technology, used in drug combinations, nano-drugs, pharmaceutical formulations, etc., can solve the problems of limiting the practical application of nucleic acid drugs, high cytotoxicity, and immune system clearance, and achieve safe and efficient intracellular drug delivery. Encapsulation efficiency, stability and safety enhancement effect

Pending Publication Date: 2022-03-01
CHINA PHARM UNIV
View PDF4 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In addition, cationic materials also have problems such as high cytotoxicity and easy clearance by the immune system, and have strong restrictions on the functional structure of the material. Therefore, there are many limitations that limit the practical application of nucleic acid drugs

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Nucleic acid drug delivery system, preparation method, pharmaceutical composition and application
  • Nucleic acid drug delivery system, preparation method, pharmaceutical composition and application
  • Nucleic acid drug delivery system, preparation method, pharmaceutical composition and application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0046] (1) Preparation of Epigallocatechin Gallate-Fe 3+ / siRNA core

[0047] Epigallocatechin gallate (EGCG) and FeCl 3 ·6H 2 O was prepared as a stock solution with RNase Free water, and siRNA was prepared as a 20 μM solution with RNase Free water. Vortex siRNA and EGCG solution for 2 hours, then mix briefly under vortex or quickly mix Fe by microfluidics 3+ solution, Fe 3+ The molar ratio to EGCG is 2:1. Incubate at room temperature for 30 minutes.

[0048] Specifically, Zetasizer 3000HS instrument particle size analyzer (Malvern Instruments, Malvern, UK) was used to measure the sample particle size and polydispersity index (PDI). At the same time, the loading efficiency of siRNA was examined by 1% agarose gel electrophoresis.

[0049] The specific results are as follows: the average particle diameter of the preparation can be controlled at 187±3.5nm, and the PDI is less than 0.3. The results of agarose gel electrophoresis figure 1 As shown, when Fe 3+ When the mo...

Embodiment 2

[0061] (1) Preparation of EGCG-Fe 3+ / siRNA / liposome

[0062] Soybean lecithin, cholesterol or cholesterol derivatives are dissolved in chloroform according to the prescription amount as the oil phase. EGCG-Fe 3+ / siRNA solution as the inner water phase W1. The inner water phase was added to the oil phase, and a W / O emulsion was formed by ultrasonication with a 300W probe under ice bath conditions. Add the W / O type emulsion dropwise to the external water phase containing the prescribed amount of egg yolk lecithin and DSPE-PEG2000, ultrasonicate in a 1000W water bath for 5-10 minutes to form a double emulsion, and evaporate under reduced pressure to remove the organic solvent to obtain EGCG-Fe 3+ / siRNA / liposome. At the same time, the particle size and polydispersity index (PDI) of the samples were measured using a Zetasizer 3000HS instrument particle size analyzer (Malvern Instruments, Malvern, UK).

[0063] The specific results are as follows: the average particle diamete...

Embodiment 3

[0078] (1) Preparation of TA-Fe 3+ / siRNA / biofilm complex

[0079] Suspend red blood cells extracted from whole blood in hypotonic buffer, sonicate for 5 minutes, collect cell membranes by centrifugation at low temperature, resuspend the collected red blood cell membranes in water at a concentration of 2 mg / ml, and mix with TA-Fe 3+ / siRNA / solution was mixed in equal volume, and the water bath was sonicated for 2 minutes. The nanoparticles are then collected by centrifugation at 4°C and 10000g for 5 minutes. The average particle diameter of the preparation is 140±2.5nm, and the PDI is less than 0.3.

[0080] (2) Preparation of TA-Fe 3+ / mRNA / biofilm complex

[0081] Platelet membranes were extracted from plasma by repeated freezing and thawing, suspended in water at a concentration of 2 mg / ml, and then the platelet membrane solution was mixed with TA-Fe 3+ / mRNA solution was mixed in equal volumes, incubated for 30 min, and then passed through 1000, 400, and 200 nm polyca...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a nucleic acid drug delivery system, a preparation method, a pharmaceutical composition and application, and the drug delivery system is a compound formed by a nucleic acid drug and polyphenol or a polyphenol metal ion complex through non-covalent interaction. Then the surface of the compound is coated with lipid and a biological membrane to form a drug delivery system which is high in encapsulation efficiency, delivery efficiency, stability, safety and preparation simplicity and convenience, and functional requirements on lipid, transfection materials and the like are reduced. The drug delivery system can be prepared into a liquid preparation through a mixing and dispersing technology, and can be further prepared into a freeze-drying preparation by adding a protective agent, so that the drug delivery system is suitable for drugs and diagnostic agents in various administration routes such as oral administration, inhalation, injection, ophthalmic administration, transdermal administration and mucous membrane administration.

Description

technical field [0001] The present invention relates to a nucleic acid drug delivery system, preparation method, pharmaceutical composition and application based on non-covalent interaction, especially to a nucleic acid drug delivery with significantly improved drug encapsulation efficiency, delivery efficiency, stability, and biological safety System, preparation method, pharmaceutical composition and application. Background technique [0002] Nucleic acid drugs have brought difficulties to the development of traditional oral and injection dosage forms due to their poor physical and chemical stability and bioavailability. In order to achieve efficient delivery of nucleic acid drugs, nano drug delivery systems such as liposomes, polymer micelles, dendrimers, and magnetic nanoparticles have been extensively studied to enhance the stability of nucleic acids in vivo and maximize their activity. But so far, there are only three types of complex preparations of nucleic acid drug...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/7088A61K48/00A61K9/51A61K47/22A61K47/02A61K47/24A61K47/28A61K47/46A61P29/00A61P35/00A61P37/02B82Y5/00B82Y40/00C12N15/87
CPCA61K31/7088A61K48/005A61K48/0008A61K9/5123A61K9/5115A61K9/5176A61K9/5192A61P29/00A61P35/00A61P37/02B82Y5/00B82Y40/00C12N15/87
Inventor 殷婷婕周建平胡程霞郑宇钊
Owner CHINA PHARM UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products